These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24018264)

  • 1. Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.
    Loo AS; Neely M; Anderson EJ; Ghossein C; McLaughlin MM; Scheetz MH
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5854-9. PubMed ID: 24018264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis.
    König C; Braune S; Roberts JA; Nierhaus A; Steinmetz OM; Baehr M; Frey OR; Langebrake C; Kluge S
    J Antimicrob Chemother; 2017 May; 72(5):1433-1440. PubMed ID: 28175308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
    Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
    Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-hemodialysis dosing of 1 vs. 2 g of ceftazidime in anuric end-stage renal disease patients on low-flux dialysis and its pharmacodynamic implications on clinical use.
    Goh JH; Lee SY; Ooi ST; Lee Soon-U L; Hee KH; Renaud CJ
    Hemodial Int; 2016 Apr; 20(2):253-60. PubMed ID: 26486806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa.
    Cojutti PG; Maximova N; Schillani G; Hope W; Pea F
    J Antimicrob Chemother; 2019 Jun; 74(6):1648-1655. PubMed ID: 30838391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling.
    Delattre IK; Hites M; Laterre PF; Dugernier T; Spapen H; Wallemacq PE; Jacobs F; Taccone FS
    Int J Antimicrob Agents; 2020 Oct; 56(4):106113. PubMed ID: 32721604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
    Bulitta JB; Landersdorfer CB; Hüttner SJ; Drusano GL; Kinzig M; Holzgrabe U; Stephan U; Sörgel F
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1275-82. PubMed ID: 20065059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S; Pai MP; Lodise TP
    J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.
    Shoji K; Bradley JS; Reed MD; van den Anker JN; Domonoske C; Capparelli EV
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2150-6. PubMed ID: 26810655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Investigation on optimal regimen of ceftazidime against infection caused by Pseudomonas aeruginosa using Monte Carlo simulation].
    Mikamo H
    Jpn J Antibiot; 2007 Dec; 60(6):387-93. PubMed ID: 18447208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.
    Nicolau DP; Nightingale CH; Banevicius MA; Fu Q; Quintiliani R
    Antimicrob Agents Chemother; 1996 Jan; 40(1):61-4. PubMed ID: 8787880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments.
    Kidd JM; Stein GE; Nicolau DP; Kuti JL
    J Clin Pharmacol; 2020 Feb; 60(2):172-180. PubMed ID: 31423601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
    Mouton JW; Punt N; Vinks AA
    Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.